Welcoming Eddie Eltoukhy as our Biotech Partner

We are extremely excited to announce Eddie Eltoukhy as our latest Partner, heading up our investments across Biotech and life sciences.

As a firm, Pear has already made some big investments in Biotech, including Guardant Health (NASDAQ: GH), Senti Bio (Series B, led by Bayer LEAPS, and going public soon), BioAge (Series C, led by A16z), Xillis (Series A, led by GV, Mubadala), and many more.

By bringing Eddie onboard as a Partner, we’re doubling down on Pear’s effort to back the next generation of innovative life science companies. Why? Because it’s estimated that the Biotech industry will be worth $2.4T by 2028, growing on the macro tailwinds of an expanding healthcare sector, favorable government and regulatory initiatives, and rising R&D investment by public and private agencies. This potential is boosted by technology trends such as plummeting DNA synthesis and sequencing costs, the advancement of AI / ML, and the increasing adoption of synthetic biology at scale.

We believe that no firm has yet to build the ideal pre-seed and seed stage investment partnership for Biotech founders, and with Eddie at the helm, we are determined to be that firm. We’ve known Eddie since he joined our portfolio company, Senti Bio, as its first business hire. Eddie oversaw Senti Bio’s growth, from seed stage to public financing, and he helped drive the execution of major biopharma partnerships with Spark Therapeutics (Roche) and BlueRock Therapeutics (Bayer). He brings both business acumen and scientific depth, with a PhD in Biological Engineering from MIT under the guidance of Professors Robert Langer and Daniel Anderson and an MBA from Stanford. Eddie also has experience at Roche / Genentech and Kala Pharmaceuticals. Learn more about Eddie’s full bio on our website.

Eddie is passionate about cutting-edge life sciences technologies, and he loves working to support visionary founders on their missions to transform human health. We’ve seen first hand what Eddie can do through our work together, and we’re confident his experience will be incredibly beneficial to both the Pear team and our founders. If you’re working on a new project in the Biotech space, please reach out to Eddie to chat more!